Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Multi-scale resting state functional reorganization in response to multiple sclerosis damage.

Tommasin S, De Giglio L, Ruggieri S, Petsas N, Giannì C, Pozzilli C, Pantano P.

Neuroradiology. 2020 Mar 18. doi: 10.1007/s00234-020-02393-0. [Epub ahead of print]

PMID:
32189024
2.

Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis.

Mantovani LG, Cozzolino P, Cortesi PA, Patti F; SA.FE. study group.

Clin Drug Investig. 2020 Apr;40(4):319-326. doi: 10.1007/s40261-020-00895-6.

PMID:
32130684
3.

Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis.

Prosperini L, Mancinelli C, Haggiag S, Cordioli C, De Giglio L, De Rossi N, Galgani S, Rasia S, Ruggieri S, Tortorella C, Pozzilli C, Gasperini C.

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):271-277. doi: 10.1136/jnnp-2019-322348. Epub 2020 Jan 23.

PMID:
31974130
4.

Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial.

Prosperini L, Castelli L, De Giglio L, Bonanno V, Gasperini C, Pozzilli C.

Neurotherapeutics. 2019 Dec 9. doi: 10.1007/s13311-019-00813-5. [Epub ahead of print]

PMID:
31820274
5.

Cesarean section in women with MS: A choice or a need?

L G, S F, S R, G B, Ma D, C A, C P.

Mult Scler Relat Disord. 2019 Nov 23;38:101867. doi: 10.1016/j.msard.2019.101867. [Epub ahead of print]

PMID:
31812874
6.

Cognitive fatigability is a quantifiable distinct phenomenon in multiple sclerosis.

Tommasin S, De Luca F, Ferrante I, Gurreri F, Castelli L, Ruggieri S, Prosperini L, Pantano P, Pozzilli C, De Giglio L.

J Neuropsychol. 2019 Nov 14. doi: 10.1111/jnp.12197. [Epub ahead of print]

PMID:
31729168
7.

Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.

Van Wijmeersch B, Singer BA, Boster A, Broadley S, Fernández Ó, Freedman MS, Izquierdo G, Lycke J, Pozzilli C, Sharrack B, Steingo B, Wiendl H, Wray S, Ziemssen T, Chung L, Margolin DH, Thangavelu K, Vermersch P.

Mult Scler. 2019 Nov 1:1352458519881759. doi: 10.1177/1352458519881759. [Epub ahead of print]

PMID:
31675266
8.

Italian consensus on treatment of spasticity in multiple sclerosis.

Comi G, Solari A, Leocani L, Centonze D, Otero-Romero S; Italian Consensus Group on treatment of spasticity in multiple sclerosis.

Eur J Neurol. 2020 Mar;27(3):445-453. doi: 10.1111/ene.14110. Epub 2019 Dec 3.

PMID:
31652369
9.

Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.

Paolicelli D, Lucisano G, Manni A, Avolio C, Bonavita S, Brescia Morra V, Capobianco M, Cocco E, Conte A, De Luca G, De Robertis F, Gasperini C, Gatto M, Gazzola P, Lus G, Iaffaldano A, Iaffaldano P, Maimone D, Mallucci G, Maniscalco GT, Marfia GA, Patti F, Pesci I, Pozzilli C, Rovaris M, Salemi G, Salvetti M, Spitaleri D, Totaro R, Zaffaroni M, Comi G, Amato MP, Trojano M; Italian MS Register.

J Neurol. 2019 Dec;266(12):3098-3107. doi: 10.1007/s00415-019-09531-6. Epub 2019 Sep 18.

PMID:
31535270
10.

Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority.

Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G.

Front Neurol. 2019 Jul 16;10:695. doi: 10.3389/fneur.2019.00695. eCollection 2019.

11.

The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).

Grimaldi AE, De Giglio L, Haggiag S, Bianco A, Cortese A, Crisafulli SG, Monteleone F, Marfia G, Prosperini L, Galgani S, Mirabella M, Centonze D, Pozzilli C, Castelli L.

PLoS One. 2019 Jul 30;14(7):e0219670. doi: 10.1371/journal.pone.0219670. eCollection 2019.

12.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5):e591. doi: 10.1212/NXI.0000000000000591. eCollection 2019 Sep.

13.

Effect of dalfampridine on information processing speed impairment in multiple sclerosis.

De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, Quartuccio E, Gasperini C, Pozzilli C.

Neurology. 2019 Aug 20;93(8):e733-e746. doi: 10.1212/WNL.0000000000007970. Epub 2019 Jul 22.

PMID:
31331968
14.

Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis.

De Giglio L, Grimaldi AE, Fubelli F, Marinelli F, Pozzilli C.

Expert Rev Neurother. 2019 May;19(5):417-429. doi: 10.1080/14737175.2019.1610393. Epub 2019 May 16.

PMID:
31094239
15.

Advances in spinal cord imaging in multiple sclerosis.

Moccia M, Ruggieri S, Ianniello A, Toosy A, Pozzilli C, Ciccarelli O.

Ther Adv Neurol Disord. 2019 Apr 22;12:1756286419840593. doi: 10.1177/1756286419840593. eCollection 2019. Review.

16.

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis.

Petsas N, De Giglio L, González-Quintanilla V, Giuliani M, De Angelis F, Tona F, Carmellini M, Mainero C, Pozzilli C, Pantano P.

Front Neurol. 2019 Mar 22;10:153. doi: 10.3389/fneur.2019.00153. eCollection 2019.

17.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

18.

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

D'Amico E, Zanghì A, Sciandra M, Borriello G, Callari G, Gallo A, Salemi G, Cottone S, Buccafusca M, Valentino P, Bossio RB, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F.

J Neurol. 2019 Feb;266(2):411-416. doi: 10.1007/s00415-018-9144-9. Epub 2018 Dec 4.

PMID:
30515629
19.

The Italian multiple sclerosis register.

Trojano M, Bergamaschi R, Amato MP, Comi G, Ghezzi A, Lepore V, Marrosu MG, Mosconi P, Patti F, Ponzio M, Zaratin P, Battaglia MA; Italian Multiple Sclerosis Register Centers Group.

Neurol Sci. 2019 Jan;40(1):155-165. doi: 10.1007/s10072-018-3610-0. Epub 2018 Nov 13. Erratum in: Neurol Sci. 2019 Apr;40(4):907.

20.

Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online.

Lavorgna L, Borriello G, Esposito S, Abbadessa G, Capuano R, De Giglio L, Logoteta A, Pozzilli C, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2019 Jan;27:239-246. doi: 10.1016/j.msard.2018.10.113. Epub 2018 Nov 5.

PMID:
30419509
21.

Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution.

Scarpazza C, Signori A, Prosperini L, Sormani MP, Cosottini M, Capra R, Gerevini S; Italian PML Group.

J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):261-267. doi: 10.1136/jnnp-2018-319208. Epub 2018 Nov 2.

PMID:
30389778
22.

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248. doi: 10.1177/1756286418803248. eCollection 2018. Review.

23.

Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.

Tommasin S, De Giglio L, Ruggieri S, Petsas N, Giannì C, Pozzilli C, Pantano P.

J Neurol. 2018 Dec;265(12):2881-2892. doi: 10.1007/s00415-018-9075-5. Epub 2018 Oct 1.

PMID:
30276520
24.

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.

Prosperini L, Annovazzi P, Boffa L, Buscarinu MC, Gallo A, Matta M, Moiola L, Musu L, Perini P, Avolio C, Barcella V, Bianco A, Farina D, Ferraro E, Pontecorvo S, Granella F, Grimaldi LME, Laroni A, Lus G, Patti F, Pucci E, Pasca M, Sarchielli P; Italian Alemtuzumab Study Group.

J Neurol. 2018 Dec;265(12):2851-2860. doi: 10.1007/s00415-018-9070-x. Epub 2018 Sep 26.

PMID:
30259178
25.

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience.

D'Amico E, Zanghì A, Callari G, Borriello G, Gallo A, Graziano G, Valentino P, Buccafusca M, Cottone S, Salemi G, Ragonese P, Bossio RB, Docimo R, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F.

Ther Adv Neurol Disord. 2018 Sep 10;11:1756286418796404. doi: 10.1177/1756286418796404. eCollection 2018.

26.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

27.

2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.

Gaetani L, Prosperini L, Mancini A, Eusebi P, Cerri MC, Pozzilli C, Calabresi P, Sarchielli P, Di Filippo M.

J Neurol. 2018 Nov;265(11):2684-2687. doi: 10.1007/s00415-018-9048-8. Epub 2018 Sep 8.

PMID:
30196327
28.

Predicting the profile of increasing disability in multiple sclerosis.

Tomassini V, Fanelli F, Prosperini L, Cerqua R, Cavalla P, Pozzilli C.

Mult Scler. 2019 Aug;25(9):1306-1315. doi: 10.1177/1352458518790397. Epub 2018 Aug 2.

29.

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.

CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3.

PMID:
30022464
30.

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.

Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3.

PMID:
29970387
31.

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.

Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6.

PMID:
29875218
32.

Balance worsening associated with nabiximols in multiple sclerosis.

Castelli L, Prosperini L, Pozzilli C.

Mult Scler. 2019 Jan;25(1):113-117. doi: 10.1177/1352458518765649. Epub 2018 Mar 13.

PMID:
29533137
33.

The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis.

Farcomeni A, Cortese A, Sgarlata E, Alunni Fegatelli D, Marfia GA, Buttari F, Mirabella M, De Fino C, Prosperini L, Pozzilli C, Grasso MG, Iasevoli L, Di Battista G, Millefiorini E.

Neuroepidemiology. 2018;50(3-4):105-110. doi: 10.1159/000487005. Epub 2018 Mar 2.

PMID:
29502114
34.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7. Erratum in: Neurology. 2020 Mar 17;94(11):504.

PMID:
29438046
35.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7. Erratum in: Neurology. 2020 Mar 17;94(11):504.

PMID:
29438041
36.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
37.

Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2018 Feb;39(2):395. doi: 10.1007/s10072-017-3226-9.

PMID:
29280018
38.

Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis.

Tona F, De Giglio L, Petsas N, Sbardella E, Prosperini L, Upadhyay N, Giannì C, Pozzilli C, Pantano P.

Radiology. 2018 Apr;287(1):267-275. doi: 10.1148/radiol.2017170311. Epub 2017 Dec 22.

PMID:
29272214
39.

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group.

J Neurol. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23.

40.

The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study.

Pappalardo A, Chisari CG, Montanari E, Pesci I, Borriello G, Pozzilli C, D'Amico E, Patti F.

Mult Scler Relat Disord. 2017 Oct;17:154-171. doi: 10.1016/j.msard.2017.07.022. Epub 2017 Jul 28.

PMID:
29055451
41.

Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Rossi F, Prosperini L, De Rossi N, Capra R, Rivanera D, Li X, Cinque P, Passeri L, Pozzilli C, Viscidi R.

Viral Immunol. 2017 Oct;30(8):622-626. doi: 10.1089/vim.2017.0039. Epub 2017 Aug 24.

PMID:
28836899
42.

Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.

Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Bargagli A; Multiple Sclerosis Study Group, Lazio Region.

Neuroepidemiology. 2017;48(3-4):171-178. doi: 10.1159/000479515. Epub 2017 Aug 9.

PMID:
28793295
43.

Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2017 Oct;38(10):1849-1858. doi: 10.1007/s10072-017-3081-8. Epub 2017 Aug 2. Erratum in: Neurol Sci. 2017 Dec 26;:.

PMID:
28770366
44.

Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.

Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M.

Neurol Sci. 2017 Oct;38(10):1841-1848. doi: 10.1007/s10072-017-3078-3. Epub 2017 Aug 1.

PMID:
28766025
45.

High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.

Gaetani L, Fanelli F, Riccucci I, Eusebi P, Sarchielli P, Pozzilli C, Calabresi P, Prosperini L, Di Filippo M.

J Neurol Sci. 2017 Aug 15;379:236-240. doi: 10.1016/j.jns.2017.06.008. Epub 2017 Jun 9.

PMID:
28716249
46.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
47.

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group.

Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22.

48.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
49.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

50.

Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.

De Giglio L, Marinelli F, Barletta VT, Pagano VA, De Angelis F, Fanelli F, Petsas N, Pantano P, Tomassini V, Pozzilli C.

CNS Drugs. 2017 Feb;31(2):161-168. doi: 10.1007/s40263-016-0401-0.

PMID:
27995531

Supplemental Content

Loading ...
Support Center